keyword
MENU ▼
Read by QxMD icon Read
search

NAI-107

keyword
https://www.readbyqxmd.com/read/27381394/the-lantibiotic-nai-107-efficiently-rescues-drosophila-melanogaster-from-infection-with-methicillin-resistant-staphylococcus-aureus-usa300
#1
Thomas T Thomsen, Biljana Mojsoska, João C S Cruz, Stefano Donadio, Håvard Jenssen, Anders Løbner-Olesen, Kim Rewitz
We used the fruit fly Drosophila melanogaster as a cost-effective in vivo model to evaluate the efficacy of novel antibacterial peptides and peptoids for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. A panel of peptides with known antibacterial activity in vitro and/or in vivo was tested in Drosophila Although most peptides and peptoids that were effective in vitro failed to rescue lethal effects of S. aureus infections in vivo, we found that two lantibiotics, nisin and NAI-107, rescued adult flies from fatal infections...
September 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/26877024/structure-and-trna-specificity-of-mibb-a-lantibiotic-dehydratase-from-actinobacteria-involved-in-nai-107-biosynthesis
#2
Manuel A Ortega, Yue Hao, Mark C Walker, Stefano Donadio, Margherita Sosio, Satish K Nair, Wilfred A van der Donk
Class I lantibiotic dehydratases dehydrate selected Ser/Thr residues of a precursor peptide. Recent studies demonstrated the requirement of glutamyl-tRNA(Glu) for Ser/Thr activation by one of these enzymes (NisB) from the Firmicute Lactococcus lactis. However, the generality of glutamyl-tRNA(Glu) usage and the tRNA specificity of lantibiotic dehydratases have not been established. Here we report the 2.7-Å resolution crystal structure, along with the glutamyl-tRNA(Glu) utilization of MibB, a lantibiotic dehydratase from the Actinobacterium Microbispora sp...
March 17, 2016: Cell Chemical Biology
https://www.readbyqxmd.com/read/26515981/advancing-cell-wall-inhibitors-towards-clinical-applications
#3
REVIEW
Sonia I Maffioli, João C S Cruz, Paolo Monciardini, Margherita Sosio, Stefano Donadio
Natural products represent a major source of approved drugs and still play an important role in supplying chemical diversity. Consistently, 2014 has seen new, natural product-derived antibiotics approved for human use by the US Food and Drug Administration. One of the recently approved second-generation glycopeptides is dalbavancin, a semi-synthetic derivative of the natural product A40,926. This compound inhibits bacterial growth by binding to lipid intermediate II (Lipid II), a key intermediate in peptidoglycan biosynthesis...
March 2016: Journal of Industrial Microbiology & Biotechnology
https://www.readbyqxmd.com/read/26512731/brominated-variant-of-the-lantibiotic-nai-107-with-enhanced-antibacterial-potency
#4
João C S Cruz, Marianna Iorio, Paolo Monciardini, Matteo Simone, Cristina Brunati, Eleonora Gaspari, Sonia I Maffioli, Elizabeth Wellington, Margherita Sosio, Stefano Donadio
We identified an Actinoallomurus strain producing NAI-107, a chlorinated lantibiotic effective against multidrug-resistant Gram-positive pathogens and previously reported from the distantly related genus Microbispora. Inclusion of KBr in the production medium of either the Actinoallomurus or the Microbispora producer readily afforded brominated variants of NAI-107, which were designated as NAI-108. The other post-translational modifications naturally occurring in this lantibiotic family (i.e., hydroxylation of Pro-14 and C-terminal decarboxylation) were unaffected by the presence of a brominated tryptophan...
November 25, 2015: Journal of Natural Products
https://www.readbyqxmd.com/read/26346738/a-novel-microbisporicin-producer-identified-by-early-dereplication-during-lantibiotic-screening
#5
Lucia Carrano, Monica Abbondi, Paola Turconi, Gianpaolo Candiani, Flavia Marinelli
With the increasing need of effective antibiotics against multi-drug resistant pathogens, lantibiotics are an attractive option of a new class of molecules. They are ribosomally synthetized and posttranslationally modified peptides possessing potent antimicrobial activity against aerobic and anaerobic Gram-positive pathogens, including those increasingly resistant to β-lactams and glycopeptides. Some of them (actagardine, mersacidin, planosporicin, and microbisporicin) inhibit cell wall biosynthesis in pathogens and their effect is not antagonized by vancomycin...
2015: BioMed Research International
https://www.readbyqxmd.com/read/25923468/distinct-mechanisms-contribute-to-immunity-in-the-lantibiotic-nai-107-producer-strain-microbispora-atcc-pta-5024
#6
Roberta Pozzi, Murray Coles, Dirk Linke, Andreas Kulik, Mulugeta Nega, Wolfgang Wohlleben, Evi Stegmann
The investigation of self-resistance in antibiotic producers is important to understand the emergence of antibiotic resistance in pathogens and to improve antibiotic production. Lantibiotics are ribosomally synthesized antibiotics that mostly target peptidoglycan biosynthesis. The actinomycete Microbispora ATCC PTA-5024 produces the lantibiotic NAI-107, which interferes with peptidoglycan biosynthesis by binding bactoprenol-pyrophosphate-coupled peptidoglycan precursors. In order to understand how Microbispora counteracts the action of its own antibiotic, its peptidoglycan composition was analysed in detail...
January 2016: Environmental Microbiology
https://www.readbyqxmd.com/read/25697059/perspectives-on-lantibiotic-discovery-where-have-we-failed-and-what-improvements-are-required
#7
EDITORIAL
Stephanie Kate Sandiford
The increasing resistance of bacteria to conventional antimicrobial therapy within both the nosocomial and community environment has enforced the urgent requirement for the discovery of novel agents. This has stimulated increased research efforts within the field of lantibiotic discovery. Lantibiotics are ribosomally synthesised, post-translationally modified antimicrobial peptides that exhibit antimicrobial activity against a range of multi-drug-resistant (MDR) bacteria. The success of these agents as a novel treatment of MDR infections is exemplified by: the clinical development of MU1140 (mutacin 1140) and NAI-107 (microbisporicin), which are in late pre-clinical trials against gram-positive bacteria; NVB302 that has completed Phase I clinical trials for the treatment of Clostridium difficile infections and; duramycin that has completed Phase II clinical trials in the treatment of cystic fibrosis...
April 2015: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/25601631/self-resistance-mechanisms-of-actinomycetes-producing-lipid-ii-targeting-antibiotics
#8
REVIEW
Evi Stegmann, Hans-Joerg Frasch, Regina Kilian, Roberta Pozzi
Glycopeptides and several lantibiotics are lipid II-targeting antibiotics produced by actinomycetes. To protect themselves from their own product, antibiotic producers developed self-resistance mechanisms. Inspection of different producer strains revealed that their resistance is not only based on a single determinant but on the synergistic action of different factors. Glycopeptide producers possess different ways to synthesize a modified peptidoglycan to prevent the binding of the glycopeptide antibiotic. One possible modification is the synthesis of peptidoglycan precursors terminating with a D-alanyl-D-lactate (D-Ala-D-Lac) rather than with a D-alanyl-D-alanine (D-Ala-D-Ala) resulting in a 1000-fold decreased binding affinity of the glycopeptide to its target...
February 2015: International Journal of Medical Microbiology: IJMM
https://www.readbyqxmd.com/read/25574687/family-of-class-i-lantibiotics-from-actinomycetes-and-improvement-of-their-antibacterial-activities
#9
Sonia I Maffioli, Paolo Monciardini, Bruno Catacchio, Carlo Mazzetti, Daniela Münch, Cristina Brunati, Hans-Georg Sahl, Stefano Donadio
Lantibiotics, an abbreviation for "lanthionine-containing antibiotics", interfere with bacterial metabolism by a mechanism not exploited by the antibiotics currently in clinical use. Thus, they have aroused interest as a source for new therapeutic agents because they can overcome existing resistance mechanisms. Starting from fermentation broth extracts preselected from a high-throughput screening program for discovering cell-wall inhibitors, we isolated a series of related class I lantibiotics produced by different genera of actinomycetes...
April 17, 2015: ACS Chemical Biology
https://www.readbyqxmd.com/read/25512404/in-vivo-pharmacokinetics-and-pharmacodynamics-of-the-lantibiotic-nai-107-in-a-neutropenic-murine-thigh-infection-model
#10
Alexander J Lepak, Karen Marchillo, William A Craig, David R Andes
NAI-107 is a novel lantibiotic compound with potent in vitro activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The purpose of this study was to examine the activity of NAI-107 against S. aureus strains, including MRSA, in the neutropenic murine thigh infection model. Serum pharmacokinetics were determined and time-kill studies were performed following administration of single subcutaneous doses of 5, 20, and 80 mg/kg body weight. The dose fractionation included total doses ranging from 1...
February 2015: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/25300322/inorganic-phosphate-is-a-trigger-factor-for-microbispora-sp-atcc-pta-5024-growth-and-nai-107-production
#11
Anna Giardina, Rosa Alduina, Giuseppe Gallo, Paolo Monciardini, Margherita Sosio, Anna Maria Puglia
BACKGROUND: NAI-107, produced by the actinomycete Microbispora sp. ATCC-PTA-5024, is a promising lantibiotic active against Gram-positive bacteria and currently in late preclinical-phase. Lantibiotics (lanthionine-containing antibiotics) are ribosomally synthesized and post-translationally modified peptides (RiPPs), encoded by structural genes as precursor peptides. The biosynthesis of biologically active compounds is developmentally controlled and it depends upon a variety of environmental stimuli and conditions...
2014: Microbial Cell Factories
https://www.readbyqxmd.com/read/24627484/the-lantibiotic-nai-107-binds-to-bactoprenol-bound-cell-wall-precursors-and-impairs-membrane-functions
#12
Daniela Münch, Anna Müller, Tanja Schneider, Bastian Kohl, Michaela Wenzel, Julia Elisabeth Bandow, Sonia Maffioli, Margherita Sosio, Stefano Donadio, Reinhard Wimmer, Hans-Georg Sahl
The lantibiotic NAI-107 is active against Gram-positive bacteria including vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus. To identify the molecular basis of its potency, we studied the mode of action in a series of whole cell and in vitro assays and analyzed structural features by nuclear magnetic resonance (NMR). The lantibiotic efficiently interfered with late stages of cell wall biosynthesis and induced accumulation of the soluble peptidoglycan precursor UDP-N-acetylmuramic acid-pentapeptide (UDP-MurNAc-pentapeptide) in the cytoplasm...
April 25, 2014: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/24459268/draft-genome-sequence-of-the-microbispora-sp-strain-atcc-pta-5024-producing-the-lantibiotic-nai-107
#13
Margherita Sosio, Giuseppe Gallo, Roberta Pozzi, Stefania Serina, Paolo Monciardini, Agnieska Bera, Evi Stegmann, Tilmann Weber
We report the draft genome sequence of Microbispora sp. strain ATCC-PTA-5024, a soil isolate that produces NAI-107, a new lantibiotic with the potential to treat life-threatening infections caused by multidrug-resistant Gram-positive pathogens. The draft genome of strain Microbispora sp. ATCC-PTA-5024 consists of 8,543,819 bp, with a 71.2% G+C content and 7,860 protein-coding genes.
2014: Genome Announcements
https://www.readbyqxmd.com/read/24422756/characterization-of-the-congeners-in-the-lantibiotic-nai-107-complex
#14
Sonia I Maffioli, Marianna Iorio, Margherita Sosio, Paolo Monciardini, Eleonora Gaspari, Stefano Donadio
NAI-107, a lantibiotic produced by Microbispora sp. 107891, shows potent activity against multi-drug-resistant bacterial pathogens. It is produced as a complex of related molecules, which is unusual for ribosomally synthesized peptides. Here we describe the identification, characterization, and antibacterial activity of the congeners produced by Microbispora sp. 107891 and by the related Microbispora corallina NRRL 30420. These molecules differ by the presence of two, one, or zero hydroxyl groups at Pro-14, by the presence of a chlorine at Trp-4, and/or by the presence of a sulfoxide on the thioether of the first lanthionine...
January 24, 2014: Journal of Natural Products
https://www.readbyqxmd.com/read/22083835/solution-structure-by-nuclear-magnetic-resonance-of-the-two-lantibiotics-97518-and-nai-107
#15
Francesca Vasile, Donatella Potenza, Barbara Marsiglia, Sonia Maffioli, Stefano Donadio
Lantibiotics 97518 and NAI-107, produced by the related genera Planomonospora and Microbispora respectively, are members of a family of nisin-related compounds. They represent promising compounds to treat infections caused by multiresistant Gram-positive pathogens. Despite their similar structure and a similar antibacterial spectrum, the two lantibiotics exhibit significant differences in their potency. To gain an insight into the structure-activity relationships, their conformational properties in solution are determined by NMR...
February 2012: Journal of Peptide Science: An Official Publication of the European Peptide Society
https://www.readbyqxmd.com/read/21220527/efficacy-of-the-new-lantibiotic-nai-107-in-experimental-infections-induced-by-multidrug-resistant-gram-positive-pathogens
#16
Daniela Jabés, Cristina Brunati, GianPaolo Candiani, Simona Riva, Gabriella Romanó, Stefano Donadio
NAI-107 is a novel lantibiotic active against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), glycopeptide-intermediate S. aureus (GISA), and vancomycin-resistant enterococci (VRE). The aim of this study was to evaluate the in vivo efficacy of NAI-107 in animal models of severe infection. In acute lethal infections induced with a penicillin-intermediate Streptococcus pneumoniae strain in immunocompetent mice, or with MRSA, GISA, and VRE strains in neutropenic mice, the 50% effective dose (ED(50)) values of NAI-107 were comparable or lower than those of reference compounds, irrespective of the strain and immune status (0...
April 2011: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/19844847/interscience-conference-on-antimicrobial-agents-and-chemotherapy-49th-annual-meeting-part-2-12-15-september-2009-san-francisco-ca-usa
#17
Ben Turner, Lisa Murch
The Interscience Conference on Antimicrobial Agents and Chemotherapy held in San Francisco included topics covering new therapeutic developments for the treatment of infectious diseases. This conference report highlights selected presentations on several antibiotics in development including a broad-spectrum penem beta-lactam antibiotic, a novel siderophore monobactam, as well as other novel antibiotics. Investigational drugs discussed include sulopenem and sulopenem etzadroxil (both Pfizer Inc), BAL-30072 (Basilea Pharmaceutica International Ltd), TP-120 and TP-787 (both Tetraphase Pharmaceuticals Inc), NAI-107 (New Anti Infectives Consortium/NexThera Biosciences) and ABI-200 (AdRem Biotech/US Department of Agriculture)...
November 2009: IDrugs: the Investigational Drugs Journal
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"